Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
Bristol Myers Faces Renewed, $6.7 Billion Lawsuit Over Delayed Cancer Drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
NICE has said Celgene's Vidaza (azacitidine) should not be funded by the National Health Service, estimating it costs the health system more than ten times as much as estimated by the manufacturer.
Under the deal, Celgene shareholders received $50 in cash plus a tradeable CVR for each share held, with the CVR entitling ...
UMB Financial plans to refile a $6.4 billion against Bristol-Myers Squibb by shareholders owning contingent value rights over its acquisition of Celgene. UMB plans to refile a lawsuit by the end ...
Celgene is pushing further into the field of neuroscience and dementia research with an alliance with Dublin-based biotech Prosena. Celgene has become a ‘big biotech’ thanks to its stellar ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback